Johnson & Johnson (JNJ) Shares Sold by Home Federal Bank of Tennessee

Home Federal Bank of Tennessee decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,128 shares of the company’s stock after selling 635 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Home Federal Bank of Tennessee’s portfolio, making the stock its 16th biggest holding. Home Federal Bank of Tennessee’s holdings in Johnson & Johnson were worth $2,393,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in JNJ. Eagle Ridge Investment Management increased its position in shares of Johnson & Johnson by 3.5% in the third quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock valued at $3,578,000 after buying an additional 928 shares in the last quarter. Oliver Luxxe Assets LLC increased its position in shares of Johnson & Johnson by 12.7% in the second quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock valued at $2,320,000 after buying an additional 1,972 shares in the last quarter. Progressive Investment Management Corp increased its position in shares of Johnson & Johnson by 6.8% in the third quarter. Progressive Investment Management Corp now owns 40,317 shares of the company’s stock valued at $5,242,000 after buying an additional 2,584 shares in the last quarter. Middleton & Co Inc MA increased its position in shares of Johnson & Johnson by 40.5% in the third quarter. Middleton & Co Inc MA now owns 39,272 shares of the company’s stock valued at $5,106,000 after buying an additional 11,315 shares in the last quarter. Finally, Sitrin Capital Management LLC increased its position in shares of Johnson & Johnson by 1.6% in the second quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock valued at $6,480,000 after buying an additional 792 shares in the last quarter. Hedge funds and other institutional investors own 67.21% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of JNJ stock opened at $125.10 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market capitalization of $341,748.06, a price-to-earnings ratio of 320.77, a P/E/G ratio of 2.03 and a beta of 0.77. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter last year, the company earned $1.58 earnings per share. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 8.11 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s payout ratio is 861.54%.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.19% of the stock is currently owned by company insiders.

A number of research analysts have recently weighed in on the company. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a research report on Thursday, January 11th. Jefferies Group set a $161.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Friday. Stifel Nicolaus raised their price target on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. BMO Capital Markets raised their price target on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $146.06.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Sold by Home Federal Bank of Tennessee” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3295722/johnson-johnson-jnj-shares-sold-by-home-federal-bank-of-tennessee.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate PennantPark Investment Co.  Will Post Quarterly Sales of $27.23 Million
Zacks: Analysts Anticipate PennantPark Investment Co. Will Post Quarterly Sales of $27.23 Million
RSP Permian  Given a $69.00 Price Target by Stephens Analysts
RSP Permian Given a $69.00 Price Target by Stephens Analysts
Sandler O’Neill Analysts Give Simmons First National  a $35.00 Price Target
Sandler O’Neill Analysts Give Simmons First National a $35.00 Price Target
Wells Fargo Downgrades Emergent BioSolutions  to Market Perform
Wells Fargo Downgrades Emergent BioSolutions to Market Perform
Targa Resources  PT Set at $53.00 by Seaport Global Securities
Targa Resources PT Set at $53.00 by Seaport Global Securities
Cognex  Raised to Buy at Zacks Investment Research
Cognex Raised to Buy at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.